U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 12 results

Status:
US Approved Rx (2019)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Brilliant Blue G is triphenylmethane dye that was developed for use in the textile industry but is now commonly used for staining proteins in analytical biochemistry. The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue ...
Status:
US Approved Rx (2019)
First approved in 1956

Class (Stereo):
CHEMICAL (ACHIRAL)



Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


GSK-1482160 is being evaluated for treatment of inflammatory pain (such as arthritis). This compound acts on P2X7 receptors, expressed by cells of innate and adaptive immunity. P2X7 receptors are involved in the production of pro-inflammatory cytokin...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


AZD9056 was developed as a selective inhibitor of the purinergic receptor P2X7, a key player in the generation and secretion of several proinflammatory cytokines. AZD 9056 participated is phase II clinical trials for osteoarthritis, inflammatory bowe...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


CE-224535 is a potent, highly selective, orally bioavailable, non-competitive antagonist of the human P2X7 receptor. Pre-clinical pharmacokinetic studies with CE-224535 indicate limited CNS penetration. In clinical trials, CE-224535 failed to demonst...
Status:
Other

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

A-740003 is a competitive antagonist of P2X purinoceptor 7 (P2X7) that has been shown to potently block proinflammatory cytokine interleukin-1β (IL-1β) release, and also is a promising candidate for the development of a radiotracer for imaging of neu...
Status:
Other

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

AZ11645373 is a potent and selective antagonist of human P2X7, that was developed by Astra Pharmaceuticals Ltd for treatment pain. AZ11645373 Inhibits BzATP-mediated calcium influx and inhibits ATP-mediated IL-1β release in vitro. AZ11645373 in addit...
KN-62 (1-[N,O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine) is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (Ca2+/CaM kinase II). In addition, it acts as an antagonist of the P2X7 receptor.
Status:
US Approved Rx (2019)
First approved in 1956

Class (Stereo):
CHEMICAL (ACHIRAL)



Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. ...
Status:
US Approved Rx (2019)
First approved in 1956

Class (Stereo):
CHEMICAL (ACHIRAL)



Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. ...

Showing 1 - 10 of 12 results